Abstract
Mutants of a catalytically inactive variant of Proteinase 3 (PR3)—iPR3-Val103 possessing a Ser195Ala mutation relative to wild-type PR3-Val103—offer insights into how autoantigen PR3 interacts with antineutrophil cytoplasmic antibodies (ANCAs) in granulomatosis with polyangiitis (GPA) and whether such interactions can be interrupted. Here we report that iHm5-Val103, a triple mutant of iPR3-Val103, bound a monoclonal antibody (moANCA518) from a GPA patient on an epitope remote from the mutation sites, whereas the corresponding epitope of iPR3-Val103 was latent to moANCA518. Simulated B-factor analysis revealed that the binding of moANCA518 to iHm5-Val103 was due to increased main-chain flexibility of the latent epitope caused by remote mutations, suggesting rigidification of epitopes with therapeutics to alter pathogenic PR3•ANCA interactions as new GPA treatments.
INTRODUCTION
Proteinase 3 (PR3) is a neutrophil serine protease targeted by antineutrophil cytoplasmic antibodies (ANCAs) in the autoimmune disease granulomatosis with polyangiitis (GPA) (1–5). To investigate how PR3 interacts with the ANCAs during inflammation and whether these interactions can be intervened by therapeutics, we developed a human PR3 mutant (iPR3-Val103) with a Val103—the major polymorphic variant at the Val/Ile polymorphic site of the wild-type human PR3 [Val/Ile in GPA patients: 64.6/35.3 (6)]—and a Ser195Ala mutation that alters the charge relay network of Asp102, His57, and Ser195 and thereby disables catalytic functioning in PR3 (7–10). This mutant recognized as many ANCA serum samples from patients with GPA as wild-type PR3 (PR3-Val103) in both immunofluorescence assay and enzyme-linked immunosorbent assay (ELISA), while the Ser195Ala mutation is close to Epitope 5 of PR3 and remote from Epitopes 1, 3, and 4 as shown in Figure 1 (8, 11). We also developed a number of variants of iPR3-Val103 in the course of our investigation (11).
One such variant, iHm5-Val103 (formerly referred to as Hm5), has Ala146, Trp218, and Leu223 from human PR3 replaced by Thr146, Arg218, and Gln223 from mouse PR3. Our initial intent of this chimeric triple mutant was to demonstrate reduced binding of ANCAs to Epitope 5 (and possibly Epitope 1 but not Epitopes 3 and 4) of the mutant because Trp218 and Leu223 reside in Epitope 5 and Ala146 is in Epitope 1 as shown in Figure 1 (11). However, as described below, we serendipitously found that a monoclonal ANCA (moANCA518) from a patient with GPA bound to Epitope 3 of iHm5-Val103 but not iPR3-Val103, although Epitope 3 is distal to the three mutations that reside in Epitopes 1 and 5 (Figure 1). This finding indicates that Epitope 3, a mutation-free epitope of iHm5-Val103, is latent in iPR3-Val103 but active in iHm5-Val103 for ANCA binding. It also indicates that the latent epitope of PR3 can be activated by remote mutations.
In this context, we raised a mechanistic question: How can a latent antibody binding site in iPR3-Val103 be activated by topologically distal mutations in iHm5-Val103? The experimental and computational results described below offer insights into this mechanistic question and open a new perspective on a possible cause and novel therapy of GPA.
MATERIALS AND METHODS
Materials
Reagents were obtained from Sigma (St. Louis, MO) unless specified otherwise. The human epithelial kidney cell line 293 used for the expression of recombinant PR3 mutants was obtained from ATCC (Rockville, MD).
iPR3-Val103 and iHm5-Val103: The cDNA constructs coding for iPR3-Val103 and iHm5-Val103 and their expression in HEK293 cells were described in detail elsewhere (11, 12). Both mutants carry a carboxy-terminal cmyc-peptide extension and a poly-His peptide extension for purification using nickel columns from GE Healthcare (Chicago, IL) and for anchoring in ELISAs as previously described and specified below (11–15).
moANCA518: DNA barcode-enabled sequencing of the antibody repertoire was performed on plasmablasts derived from a PR3-targeting ANCA (PR3-ANCA) positive patient as described elsewhere for rheumatoid arthritis and Sjögren syndrome (16–18). Phylograms of the antibody repertoires revealed clonal families of affinity matured antibodies with shared heavy and light chain VJ usage. Twenty-five antibodies were selected for recombinant expression (18) and tested for reactivity with recombinant ANCA antigens [including myeloperoxidase (15), human neutrophil elastase (19–21), iPR3-Val103, and iHm5-Val103] using the ELISA. As described in Results, one antibody bound iHm5-Val103 but not iPR3-Val103 and is termed moANCA518, whereas none of the other 24 antibodies bound either of the two PR3 antigens or other ANCA antigens.
Epitope-specific anti-PR3 moAbs: PR3G-2 (22) was a gift from C.G.M. Kallenberg of the University of Groningen. WGM2 (11, 23) was purchased from Hycult Biotech Inc (Wayne, PA). MCPR3-3 was made as previously described (8, 11).
Enzyme-linked immunosorbent assays
ELISAs used for detection of PR3-ANCA were described in detail elsewhere (12, 13, 15). In brief, either purified PR3 mutants or culture media supernatants from PR3 mutant expressing 293 cell clones diluted in the IRMA buffer (0.05 mM Tris-HCl, 0.1 M NaCl, pH 7.4, and 0.1% bovine serum albumin) were incubated in Pierce® nickel-coated plates from Thermo Fisher Scientific (Waltham, CA) for 1 hour at room temperature; control wells were incubated with the IRMA buffer only. The plates were washed three times with Tris-buffered saline (TBS; 20 mM Tris-HCl, 500 mM NaCl, pH 7.5, and 0.05% Tween 20) in between steps. The ANCA-containing serum samples were diluted 1:20 in TBS with 0.5% bovine serum albumin and incubated in the plates with or without the PR3 mutants for 1 hour at room temperature. The PR3•ANCA complexation was detected after incubation for 1 hour at room temperature with alkaline phosphatase-conjugated goat anti-human IgG (1:10,000 dilution). P-Nitrophenyl phosphate was used as substrate at a concentration of 1 mg/mL. The net UV absorbance was obtained by spectrophotometry at 405 nm after 30 minutes of exposure. Similarly, when epitope-specific anti-PR3 moAbs were used to immobilize iHm5-Val103 on Maxisorp® plates from Invitrogen (Carlsbad, CA), complexation of moANCA518 with the antigen was detected after incubation of HRP-conjugated anti-human IgG antibody (1:250 dilution) for 1 hour at room temperature; 3,3’,5,5’-tetramethylbenzidine (Thermo Fisher Scientific®) was used as substrate, and the net UV absorbance was obtained by spectrophotometry at 450 nm after 15 minutes of exposure.
Western blots
Non-reductive, purified PR3 mutant proteins were loaded (1 µg/lane) onto 12% Tris-HCl gels from BioRad (Hercules, CA). The SDS gel electrophoresis was performed at 180 volts for 35 minutes. The proteins were transferred from gels to nitrocellulose membranes, which were subsequently washed with TBS, blocked for 45 minutes at room temperature with TBS with 0.2% non-fat dry milk. The membranes were then washed twice with TBS with 0.1% Tween 20. Monoclonal antibodies (0.5–1.0 µg/mL) were incubated on the membranes overnight at 4 °C. The membranes were then washed twice with TBS with 0.1% Tween 20 and incubated with goat anti-human or anti-mouse IgG HRP conjugates, diluted to 1:20,000, for 20 minutes at room temperature. The membranes were washed again and developed with the Pierce ECL Western Blotting Substrate kit from Thermo Fisher Scientific (Waltham, MA).
Statistical analysis
SPSS® Statistics for MacOS, version 25 from IBM (Armonk, NY, USA) was used to calculate the means and standard errors of 3–5 repeat experiments and to compare the means between groups with the two-tailed paired t-test.
Initial conformations of PR3 variants
The initial conformation of PR3-Ile103 (residues 16–239; truncated for atomic charge neutrality) was taken from the crystal structure of PR3 (24). The initial conformations of the corresponding PR3-Val103 and iPR3-Val103 (residues 16–239) were taken from the initial PR3-Ile103 conformation with mutations of Ile103Val alone and Ile103Val together with Ser195Ala, respectively. The initial conformation of iHm5-Val103 (residues 16–238; truncated for atomic charge neutrality) was taken from the initial PR3-Ile103 conformation with mutations of Ala146Thr, Trp218Arg, Leu223Gln, Ile103Val, and Ser195Ala. The crystallographically determined water molecules with residue identifiers of 246–249, 257–259, 261–263, 268, 270, 274–276, 279, 280, 291, 292, 296, 298, 307, 309, and 317 were included in all four conformations. The AMBER residue names of ASP, GLU, ARG, LYS, HID, and CYX were used for all Asp, Glu, Arg, Lys, His, and Cys residues, respectively. All initial conformations were refined via energy minimization using the SANDER module of AMBER 11 (University of California, San Francisco) and forcefield FF12MClm (25) with a dielectric constant of 1.0, a cutoff of 30.0 Å for nonbonded interactions, and 200 cycles of steepest descent minimization followed by 100 cycles of conjugate gradient minimization.
Molecular dynamics simulations
Each of the four energy-minimized conformations described above was solvated with 5578 (for iHm5-Val103) or 5536 (for all other variants) TIP3P (26) water molecules (using “solvatebox PR3 TIP3BOX 8.2”) and then energy-minimized for 100 cycles of steepest descent minimization followed by 900 cycles of conjugate gradient minimization using SANDER of AMBER 11 to remove close van der Waals contacts. The initial solvation box size was 58.268 × 68.409 × 65.657 Å3 (for iHm5-Val103) or 67.337 × 66.050 × 58.335 Å3 (for all other variants). The resulting system was heated from 5 K to 340 K at a rate of 10 K/ps under constant temperature and constant volume, then equilibrated for 106 timesteps under a constant temperature of 340 K and a constant pressure of 1 atm using the isotropic molecule-based scaling. Finally, 20 distinct, independent, unrestricted, unbiased, isobaric–isothermal, 316-ns molecular dynamics (MD) simulations of the equilibrated system with forcefield FF12MClm (25) were performed using PMEMD of AMBER 11 with a periodic boundary condition at 340 K and 1 atm. The 20 unique seed numbers for initial velocities of the 20 simulations were taken from Ref. (27). All simulations used (i) a dielectric constant of 1.0, (ii) the Berendsen coupling algorithm (28), (iii) the particle mesh Ewald method to calculate electrostatic interactions of two atoms at a separation of >8 Å (29), (iv) Δt = 1.00 fs of the standard-mass time (25), (v) the SHAKE-bond-length constraint applied to all bonds involving hydrogen, (vi) a protocol to save the image closest to the middle of the “primary box” to the restart and trajectory files, (vii) a formatted restart file, (viii) the revised alkali and halide ion parameters (30), (ix) a cutoff of 8.0 Å for nonbonded interactions, (x) a uniform 10-fold reduction in the atomic masses of the entire simulation system (both solute and solvent), and (xi) default values of all other inputs of the PMEMD module. The forcefield parameters of FF12MClm are available in the Supporting Information of Ref. (31). All simulations were performed on a cluster of 100 12-core Apple Mac Pros with Intel Westmere (2.40/2.93 GHz).
Alpha carbon B-factor calculation
In a two-step procedure using PTRAJ of AmberTools 1.5, the B-factors of alpha carbon (Cα) atoms in PR3 were calculated from all conformations saved at every 103 timesteps during 20 simulations of the protein using the simulation conditions described above except that (i) the atomic masses of the entire simulation system (both solute and solvent) were uniformly increased by 100-fold relative to the standard atomic masses, (ii) the simulation temperature was lowered to 300 K, and (iii) the simulation time was reduced to 500 ps. The first step was to align all saved conformations onto the first saved conformation to obtain an average conformation using the root mean square fit of all Cα atoms. The second step was to perform root mean square fitting of all Cα atoms in all saved conformations onto the corresponding atoms of the average conformation. The Cα B-factors were then calculated using the “atomicfluct” command in PTRAJ. For each protein, the calculated B-factor of any atom in Table S2 was the mean of all B-factors of the atom derived from 20 simulations of the protein. The standard error (SE) of a B-factor was calculated according to Eq. 2 of Ref. (32). The SE of the average Cα B-factor of each PR3 variant was calculated according to the standard method for propagation of errors of precision (33). The 95% confidence interval (95%CI) of the average Cα B-factor was obtained according to the formula mean ± 1.96×SE because the sample size of each PR3 variant exceeded 100.
Conformational cluster analysis and root mean square deviation calculation
The conformational cluster analyses were performed using CPPTRAJ of AmberTools 16 with the average-linkage algorithm (34), epsilon of 3.0 Å, and root mean square coordinate deviation on all Cα atoms of the proteins (Table S1). Cα root mean square deviations (CαRMSDs) were manually calculated using ProFit V2.6 (http://www.bioinf.org.uk/software/profit/). The first unit of the crystal structure of the PR3 tetramer and the time-averaged conformation (without energy minimization) of the most populated cluster were used for the CαRMSD calculation and Figure 3.
RESULTS
In characterizing moAbs identified and cloned from B cells in patients with GPA, we found that one of these, moANCA518, bound to iHm5-Val103 but not iPR3-Val103 (Figure 2A) according to the ELISA using iHm5-Val103 and iPR3-Val103 both of which contain a C-terminal poly-His tag for anchoring the antigens without perturbing the folded conformations of the antigens and without blocking the epitopes of the antigens (12). Further, the binding of moANCA518 to iHm5-Val103 was dose dependent (Figure 2A) and confirmed by the Western blot under non-reducing conditions (Figure S1) as well as by ELISAs using untagged PR3 variants (data not shown). This serendipitous finding prompted us to investigate how the triple chimeric mutations in iHm5-Val103 changed the conformation of iPR3-Val103 and consequently the antigenicity to moANCA518.
Accordingly, we developed computer models of PR3-Val103, iPR3-Val103, and iHm5-Val103 to understand how mutations of these variants affect the ANCA-binding capabilities of the four reported epitopes of PR3 (11). These models were derived from MD simulations using our published forcefield and simulation protocol (25), which reportedly folded fast-folding proteins in isobaric–isothermal MD simulations to achieve agreements between simulated and experimental folding times within factors of 0.69–1.75 (35) and are hence suitable for predicting in vivo conformations of PR3 and its variants. The initial conformations of the three variants used in these simulations were derived from the PR3-Ile103 crystal structure (24) because experimentally determined structures of these variants have been unavailable to date. Although small differences in the time-averaged main-chain conformations of two surface loops (Loops 3 and 5) between iHm5-Val103 and PR3-Val103 (or between iHm5-Val103 and iPR3-Val103) were observed (Figure 3), the overall conformations of the three variants resembled one another according to the Cα root mean square deviations of ≤1.63 Å (Table S1). Given these conformational properties, we could not determine how mutations of these variants affect the ANCA-binding capabilities of the PR3 epitopes, primarily because these surface loops are highly flexible and lack the time dimension (due to time-averaging) that is required for immunological function analysis (36).
To take the time dimension into account, we turned our attention to the dynamic properties of the PR3 variants. It is well-known that a folded protein is fluid-like with fluctuations in atomic position on the picosecond timescale and that the dynamics of these atomic displacements are dominated by collisions with neighboring atoms involving reorientation of side chains or localized portions of the backbone (37). Two seminal studies have also shown that the crystallographically determined high B-factors of a protein fragment are linked to the antigenicity of the fragment (38, 39). This link indicates that the crystallographically determined B-factor—defined as 8π2〈u2〉 to reflect the displacement u of the atom from its mean position, thermal motions, local mobility, or the uncertainty of the atomic mean position (40–48)—can be used to aid the identification and characterization of epitopes.
However, the crystallographically determined B-factor of an atom reflects not only the thermal motion or local mobility of the atom but also conformational and static lattice disorders of the atom, and even the refinement error in determining the mean position of the atom (43, 45, 47, 49). Therefore, using crystallographically determined B-factors to investigate epitopes requires the comparison of B-factors of different crystal structures of the same protein, which are in different space groups and obtained with different refinement procedures at different resolutions, in order to identify the B-factors that reflect the local mobility of the protein (49).
This requirement can be avoided by using simulated B-factors derived from MD simulations on a picosecond timescale because simulated B-factors are devoid of refinement errors and conformational and static lattice disorders. In addition, local motions, such as those of backbone N–H bonds, occur on the order of tens or hundreds of picoseconds (50).
In this context, we calculated the Cα B-factors of PR3-Val103, iPR3-Val103, and iHm5-Val103 from MD simulations on a 50-ps timescale using our published forcefield (25) and method (51). The mean Cα B-factors of PR3-Val103, iPR3-Val103, and iHm5-Val103 were 6.84 Å2 (95%CI: 6.75–6.94 Å2), 6.91 Å2 (95%CI: 6.82–7.00 Å2), and 7.13 Å2 (95%CI: 7.03–7.24 Å2), respectively. Given these findings, we concluded that any surface loop is highly mobile and hence potentially antigenic if the mean Cα B-factor of the loop was >9.00 Å2. This conservative cutoff of 9.00 Å2 was based on the mean Cα B-factors of all PR3 variants used in this study (6.84, 6.91, and 7.13 Å2). According to this criterion, PR3-Val103 has 10 potentially antigenic surface loops, and iPR3-Val103 and iHm5-Val103 have 11 each (Figure 4). Consistent with the two seminal reports (38, 39), all of these potentially antigenic loops identified a priori by using simulated B-factors fall within all four known epitopes of PR3 (11), demonstrating a clear association between a loop with a high mean simulated Cα B-factor and the experimentally determined antigenicity of the loop.
Further, we found that the Ser195Ala mutation caused no significant reduction in the mean Cα B-factor of any of the 10 potentially antigenic surface loops in PR3-Val103 (Figure 4A). This finding implies that the Ser195Ala mutation does not impair the ANCA-binding capability of any of the four epitopes of iPR3-Val103, and it explains our reported observation that iPR3-Val103 recognizes as many ANCA serum samples as PR3-Val103 does (8).
We also found the mean Cα B-factors of Loop 3B in iPR3-Val103 (possessing Ala146, Trp218, and Leu223) and iHm5-Val103 (possessing Thr146, Arg218, and Gln223) to be 6.9 Å2 (95%CI: 6.8–7.0 Å2) and 12.8 Å2 (95%CI: 12.3–13.2 Å2), respectively (Figure 4B). According to the afore-described antigenicity criterion of 9.00 Å2, these means suggest that the three chimeric mutations make Loop 3B (a mutation-free loop) more mobile in iHm5-Val103, despite large separations between Epitope 3 of PR3 and the chimeric mutation sites (∼32 Å, ∼32 Å, and ∼31 Å from the Cα atom of Gln122 in Epitope 3 to the Cα atoms of Ala146, Trp218, and Leu223, respectively, at the chimeric mutation sites). The higher mobility of Loop 3B in iHm5-Val103 relative to that in iPR3-Val103 is also evident from the slight loop contraction (due to time-averaging) of Loop 3B in iHm5-Val103 shown in Figure 3. Therefore, Epitope 3 of iHm5-Val103 could bind ANCAs, whereas the ANCA-binding capability of Epitope 3 of iPR3-Val103 would be rather limited.
We subsequently repeated the afore-described ELISAs in the presence of epitope-specific moAbs that target either Epitope 1 or 3 of PR3. Consistently, we found that PR3G-2 that targets Epitope 1 of PR3 (22) did not affect the binding of moANCA518 to iHm5-Val103, whereas MCPR3-3 and WGM2, both of which recognize Epitope 3 of PR3 (11), reduced and abolished the moANCA518 binding (p < 0.01; Figure 2B), respectively. We also confirmed the binding of moANCA518 primarily to Epitope 3 of iHm5-Val103 using Fabs from epitope-specific moAbs that target Epitope 2 or 5 of PR3 (8, 11, 52) (data not shown).
DISCUSSION
In view of the data above, we suggest a new mechanism for epitope activation of PR3: Remote mutations can increase the local mobility (i.e., main-chain flexibility) of a latent epitope of PR3, which facilitates the conformational adaptation required for antibody binding and thereby activate the latent epitope. This type of exquisite epitope activation—achieved either in vitro by remote mutations as we demonstrated or in vivo conceivably by remote polymorphisms or by remote protein•ligand binding including allosteric binding with an autoantibody—may be a fundamental feature of GPA. There is evidence that increased mobility of Epitope 3 occurs in vivo as more than 50% of serum samples from patients with GPA preferentially bind iHm5-Val103 (53). It is worth noting that the latent epitope activation described here conceptually differs from the exposure of cryptic epitopes caused by citrullination (viz., post-translational conversion of arginine to citrulline) (54). The latent epitope activation is due to the significant increase of main-chain flexibility of Loop 3B shown in Figure 4B caused by the three remote mutations, whereas the cryptic epitope exposure is reportedly due to conformational changes triggered by multiple citrullinations (54). The latent epitope activation does not involve conformational changes as the remote mutations do not significantly change the main-chain conformation of Loop 3B shown in Figure 3B. It is also worth noting that identifying PR3 mutations in patients with GPA that can increase the Epitope 3 mobility is difficult because other factors such as remote protein•ligand interactions may also increase the latent epitope mobility in vivo, namely, it is challenging to identify the cause of the latent epitope activation in vivo.
Nevertheless, knowing the increased mobility of Epitope 3 of iHm5-Val103 responsible for its binding to moANCA518 alone may have implications for the development of novel, effective treatments of GPA that aim to disrupt the pathogenic autoantibody•autoantigen interactions in GPA by reducing the mobility of epitopes targeted by PR3-targeting ANCAs (PR3-ANCAs). For example, the present finding may explain in principle why a monoclonal antibody strategy (that targets native PR3 and prevents binding of pathogenic PR3-ANCAs to the PR3 that is not in itself pathogenic) is of advantage for disrupting the autoantibody•autoantigen interactions over the molecular decoy strategy (that targets pathogenic autoantibodies). For the latter, large numbers of decoys are required to block a stock of distinct, pathogenic PR3-ANCAs. The DNA recombination and affinity maturation mechanisms, which create diversity and potency in specificity of antibodies, can potentially lead to resistance against the decoys. For the former, only one or a few small-molecule or protein (e.g., monoclonal antibody) binders are required to rigidify B-cell epitopes of PR3 and consequently make the autoantigen inaccessible to a repertoire of distinct, pathogenic PR3-ANCAs, thus obviating mechanisms that could potentially lead to resistance against such binders.
AUTHOR CONTRIBUTIONS
D.R.N. and U.S. initiated the collaboration project. U.S. and D.E.J. designed the PR3 variants and ANCA-binding experiments. M.C.M., G.E.T., A.M.H., and D.R.N. performed ANCA-binding experiments. Y.-P.P. designed and performed B-factor calculations. D.E., W.V., and W.H.R. discovered moANCA518. Y.-P.P., U.S., and D.E.J. wrote the manuscript. All authors contributed to revisions of the manuscript.
FUNDING
This work was supported by the US Army Research Office (W911NF-16-1-0264; to Y.-P.P.), the Connor Group Foundation (to U.S.), the Mayo Foundation for Medical Education and Research (to Y.-P.P. and U.S.), and the European Union’s Horizon 2020 research and innovation program under grant agreement No 668036 (RELENT; to D.E.J.). Responsibility for the information and views in this study lies entirely with the authors.
Conflict of Interest Statement
Daniel Emerling and Wayne Volkmuth were employed by Atreca, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
ACKNOWLEDGEMENT
The authors wish to thank Dr. C.G.M. Kallenberg of the University of Groningen for providing us with epitope-specific anti-PR3 moAb PR3G-2 as a gift. This manuscript has been released as a pre-print at bioRxiv (doi: 10.1101/559963).